On March 26, 2026, Arcadia Biosciences, Inc. (Nasdaq: RKDA) announced its financial results for the fourth quarter and full year ended December 31, 2025. The company reported total revenues of $901,000 for the fourth quarter, a decrease of $315,000 or 26% compared to the same period in 2024. For the full year, revenues decreased by $187,000 or 4%, totaling $4.858 million, despite a 17% increase in sales from its Zola coconut water brand. The decline in overall revenue was attributed to lower Zola sales and higher deductions, as well as the absence of prior year sales from GLA oil. The company also reported a net loss attributable to common stockholders of $1.336 million for Q4 2025, improving from a loss of $4.064 million in Q4 2024. For the full year, the net loss was $2.339 million, down from $7.038 million in 2024. The company has taken steps to improve its balance sheet, including the exercise of preferred investment options that yielded $2.1 million in gross proceeds. However, the termination of a proposed business combination with Roosevelt Resources adds uncertainty to its strategic outlook. Overall, while there are positive developments in terms of cost reductions and Zola's growth, the revenue decline and ongoing challenges suggest a cautious outlook for investors.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.